RF Delivery Receives CE Mark
Transdermal device ViaDerm, from TransPharma Medical (Northern Ind. Zone, Lod, Israel), which uses radio frequency waves to transmit medication into skin substrates, recently received CE mark approval. This European conformity labeling shows that a product has met safety standards and requirements.
The ViaDerm is a reusable, battery-powered, hand-held device that holds a disposable microelectrode array. Medicated patches held in the array are then applied to the skin. Upon application, proprietary RF-microchannel technology transmits the medication. The patch then seals the affected area.
Last summer, the manufacturer was awarded the 2008 Frost & Sullivan European Transdermal Drug Delivery Product Innovation Award. Sylvia Miriyam Findlay, a research analyst at Frost & Sullivan, said, “TransPharma Medical has constantly worked to spread its novel technology for transdermal drug delivery in therapeutic areas such as endocrine, pain, osteoporosis, and diabetes.”
The treatment is now in Phase II clinical trials for patients with osteoporosis, with the drug ViaDerm-hPTH (1-34), a transdermal hPTH (1-34) product. The device uses currents to create tiny pores, 100 microns in size, to allow molecules to pass through to subcutaneous capillaries and replaces daily painful injections that patients would otherwise use to deliver the medication.